Cord blood transplant was very attractive a few years ago because the graft is there so you can get the graft transplant in days and not in weeks because there is more tolerance so there is less graft-versus disease maybe some unique cells in cord blood you know the CD4 cytotoxic cells so there are some data that the graft versus leukemia effect from cord blood is stronger than in peripheral blood you know and then a New England paper from Seattle from Professor Milano in which you know, and then a New England paper from Seattle from Professor Milano in which, you know, MRD negativity is higher in cord blood transplant compared to unrelated transplant and some other data from UK that support this notion...
Cord blood transplant was very attractive a few years ago because the graft is there so you can get the graft transplant in days and not in weeks because there is more tolerance so there is less graft-versus disease maybe some unique cells in cord blood you know the CD4 cytotoxic cells so there are some data that the graft versus leukemia effect from cord blood is stronger than in peripheral blood you know and then a New England paper from Seattle from Professor Milano in which you know, and then a New England paper from Seattle from Professor Milano in which, you know, MRD negativity is higher in cord blood transplant compared to unrelated transplant and some other data from UK that support this notion. The main issue with cord blood was the slow engraftment because low number of cells, so patients were usually hospitalized for a long period in high transplant-related mortality. But with the new technique of expansion of cord blood, you can overcome, and we just wrote with Professor Shimoni a commentary in Haematologica in which, I mean, patient researcher, instead of collecting cord blood, actually collect, you know, peripheral blood from children that had, you know, phlebotomies, medical phlebotomies. But still, you know, I mean, with the progress that we have with haploidentical transplant and with PTCy, although in this year there was a study from the DKMS that, you know, didn’t show the beneficial of PTCy over ATG, I would say that haploidentical is much easier and with less transplant-related mortality, much cheaper, less hospitalization days. So I would not, if I need to put my money, I will not put it on the cord blood in adults. But there are, in children, genetic diseases, some indication that cord blood are still, you know, valid.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
